Activating epidermal growth factor receptor (EGFR) variants are the second most common oncogenic driver event in non-small cell lung cancer (NSCLC) and remain the most common targetable alteration [1,2]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.